Review





Similar Products

hla b7  (Novus Biologicals)
88
Novus Biologicals hla b7
Figure 1. Most—but not all—healthy donors demonstrate preexisting T-cell immune memory to phosphopeptides displayed on cancer cells. Summary response data for CD8þCD45ROþ T cells from healthy donors (HD) stimulated once in vitro with peptide-pulsed autologous mDCs and cultured for 14 days, measured in triplicate wells in an IFNg ELISpot assay. Data represent a minimum of 3 experiments for each peptide to which a response was observed in a donor. Peptides to which responses were not observed initially may have been analyzed in fewer experiments. A, Responses of <t>HLA-A2þ</t> donors to the indicated HLA-A2–restricted peptides. B, Responses of HLA-B7þ donors to <t>HLA-B7–restricted</t> peptides. The bottom portion of B presents data for 5 HLA-B7–restricted phosphopeptides that were analyzed for HD43,HD44, HD67, and HD89 because of limited sample availability. Insufficient PBMCs were available from HD67 and HD89 to assess responses against the larger cohort of HLA-B7–restricted phosphopeptides.
Hla B7, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hla b7/product/Novus Biologicals
Average 88 stars, based on 1 article reviews
hla b7 - by Bioz Stars, 2026-04
88/100 stars
  Buy from Supplier

Image Search Results


Figure 1. Most—but not all—healthy donors demonstrate preexisting T-cell immune memory to phosphopeptides displayed on cancer cells. Summary response data for CD8þCD45ROþ T cells from healthy donors (HD) stimulated once in vitro with peptide-pulsed autologous mDCs and cultured for 14 days, measured in triplicate wells in an IFNg ELISpot assay. Data represent a minimum of 3 experiments for each peptide to which a response was observed in a donor. Peptides to which responses were not observed initially may have been analyzed in fewer experiments. A, Responses of HLA-A2þ donors to the indicated HLA-A2–restricted peptides. B, Responses of HLA-B7þ donors to HLA-B7–restricted peptides. The bottom portion of B presents data for 5 HLA-B7–restricted phosphopeptides that were analyzed for HD43,HD44, HD67, and HD89 because of limited sample availability. Insufficient PBMCs were available from HD67 and HD89 to assess responses against the larger cohort of HLA-B7–restricted phosphopeptides.

Journal: Cancer Immunology Research

Article Title: Characteristics of immune memory and effector activity to cancer-expressed MHC class I phosphopeptides differ in healthy donors and ovarian cancer patients

doi: 10.1158/2326-6066.cir-21-0111

Figure Lengend Snippet: Figure 1. Most—but not all—healthy donors demonstrate preexisting T-cell immune memory to phosphopeptides displayed on cancer cells. Summary response data for CD8þCD45ROþ T cells from healthy donors (HD) stimulated once in vitro with peptide-pulsed autologous mDCs and cultured for 14 days, measured in triplicate wells in an IFNg ELISpot assay. Data represent a minimum of 3 experiments for each peptide to which a response was observed in a donor. Peptides to which responses were not observed initially may have been analyzed in fewer experiments. A, Responses of HLA-A2þ donors to the indicated HLA-A2–restricted peptides. B, Responses of HLA-B7þ donors to HLA-B7–restricted peptides. The bottom portion of B presents data for 5 HLA-B7–restricted phosphopeptides that were analyzed for HD43,HD44, HD67, and HD89 because of limited sample availability. Insufficient PBMCs were available from HD67 and HD89 to assess responses against the larger cohort of HLA-B7–restricted phosphopeptides.

Article Snippet: Cells were regularly assessed by flow cytometry for expression of HLA-A2 (using an APC-conjugated antibody specific for HLA-A2, clone BB7.2, BD; cat #BDB561341) and HLA-B7 (using either a PE-conjugated antibody specific for HLA-B7, clone BB7.1, Novus Biologicals; cat #NB10064159PE, or a PE-conjugated antibody specific forHLA-B7, clone REA176,Miltenyi; cat #130-118-471).

Techniques: In Vitro, Cell Culture, Enzyme-linked Immunospot